Efficacy and safety of tenofovir alafenamide fumarate in patients with first-time hepatitis B virus-related decompensated cirrhosis
Journal Title: Journal of Clinical Hepatology - Year 2024, Vol 40, Issue 10
Abstract
[Objective] To investigate the application value of tenofovir alafenamide fumarate （TAF） in patients with first-time hepatitis B virus-related decompensated cirrhosis （HBV-DC） and its impact on renal function and lipid metabolism. [Methods] A total of 57 patients with first-time HBV-DC who were hospitalized and received TAF antiviral therapy in The Affiliated Hospital of Xuzhou Medical University from January 1， 2020 to December 31， 2022 were enrolled， and all of them received TAF antiviral therapy. Related data were collected at baseline and at weeks 12， 24， and 48 of treatment， including virological and serological indicators， liver and renal function， serum phosphorus， and blood lipids. The paired t-test or single group repeated measures ANOVA were used for comparison of normally distributed continuous data， the Friedman test was used for comparison of non-normally distributed continuous data， and the chi-square test or the Fisher’s exact test were used for categorical data. [Results] A total of 52 patients completed the 48 weeks of follow-up. After 12， 24， and 48 weeks of treatment， the patients achieving HBV DNA seroconversion accounted for 38.5%， 63.5%， and 84.6%， respectively； the alanine aminotransferase normalization rate were 71.2%， 82.7%， and 82.7%， respectively； the proportion of the patients with Child-Pugh class A disease increased to 55.8%， 73.1%， and 92.3%， respectively. Within the 48 weeks of treatment， there were significant increases in the levels of cystatin C （χ2=35.163， P<0.001） and serum phosphorus （F=8.600， P<0.001） and low-density lipoprotein cholesterol （χ2=10.064，P=0.018）. The ratio of total cholesterol/high-density lipoprotein cholesterol decreased continuously from 3.61 （2.61～5.84） to 3.27 （2.70～4.36） （χ2=5.000， P=0.172）. [Conclusion] TAF can rapidly inhibit HBV replication and significantly improve liver function in HBV-DC patients， with no significant impact on renal function. However， blood lipid should be closely monitored.
Authors and Affiliations
Xinxin RONG, Yuanyuan XU, Guangde YANG, Xia WANG, Juanjuan FU, Li LI, Xiucheng PAN
Keywords
Related Articles
- EP ID EP751055
- DOI 10.12449/JCH241013
- Views 37
- Downloads 0
Association of TRIM29 with HBV replication and the antiviral effect of pegylated interferon α-2b
[Objective] To preliminarily investigate the association of TRIM29 with HBV replication and the antiviral effect of pegylated interferon α-2b （PEG-IFN-α-2b）， since TRIM29 protein is involved in the development and pro...
Role of peripheral clock genes in the progression， prevention， and treatment of nonalcoholic steatohepatitis
As a severe clinical manifestation of nonalcoholic fatty liver disease， nonalcoholic steatohepatitis （NASH） is characterized by lipid deposition and inflammatory damage in the liver. At present， clinical medications...
The mechanism of autophagy inducing drug resistance of hepatocellular carcinoma
Treatment resistance of hepatocellular carcinoma （HCC） is an important factor restricting its treatment outcome. Autophagy is a process involving multiple steps and targets and is closely associated with the proliferat...
Current status of ex vivo liver resection and autotransplantation in treatment of benign liver lesions
Benign liver lesions mainly include hepatic hemangioma， focal nodular hyperplasia of the liver， hepatocellular adenoma， and hepatic angiomyolipoma. Hepatic alveolar echinococcosis is a type of parasitic disease， and...
Effect of Qizhu prescription on a mouse model of non-alcoholic fatty liver disease incluced by high-fat， high-fructose， and high-cholesterol diet and its mechanism
[Objective] To investigate the therapeutic effect and mechanism of action of Qizhu prescription in mice with non-alcoholic fatty liver disease （NAFLD）. [Methods] A total of 60 male C57BL/6J mice were randomly divided i...